The Fly On the Wall
In a report published Tuesday, Piper Jaffray analyst Erinn E. Murphy maintained an Overweight rating on Fitbit, Inc. The analyst expects the company to report robust results for Q2 when it releases its first reported quarterly earnings report as a publicly traded company on August 5.
The analyst expects the company’s Q2 sales and EPS to beat the estimates, driven by new product adoption. “More importantly, we are expecting a guide-up on Q3 given continued momentum of new product and recently increased manufacturing capacity for Charge HR. Murphy also mentioned that the long-term positive view of the company was based on its leadership position in the wearable space, as well as the opportunity for Fitbit to reach a wide addressable market, both internationally and domestically. Given the long-term growth prospects we think FIT deserves to trade similar to high-growth consumer facing brands.”
Good Looking Company.
Big Money in Eye Drugs For Big Pharmas.
Correct...This is the deal of the century...lock and loaded.
Sentiment: Strong Buy
Michael Yee ( RBC Analyst ) Best In Business- Good Link
Sentiment: Strong Buy
Low Float $40's Today
Virtual devices $15,000 each
Leerink Outperform Rating On Fitbit- Here's Why Link
The Fly On The Wall
Breaking News Feed
Fitbit analyst commentary
Leerink bullish on Fitbit into first earnings call. Leerink analysts Steven Wardell says an analysis of recent consumer data keeps him bullish on Fitbit (FIT) into the company's first earnings conference call on August 5. Fitbit continues to dominate the Best Seller rankings on Amazon (AMZN) while Google (GOOG) Trends data show interest in Fitbit continues to "dwarf" rvals,Wardell tells investors in a research note. The analyst expects continued strength for Fitbit's unit growth and selling prices. He reiterates an Outperform rating on the stock.
By : Ryan Barnes
Zynerba transdermal delivery tech has 10 patents in the United States, and more than 30 abroad. Zynerba is the only company with IP in the area of transdermal cannabis therapeutics. The total “end market potential” for the indications Zynerba could treat amounts to over $7 billion, so there is plenty of runway for success. GW Pharmaceuticals (NASDAQ: GWPH) was about the same size company as Zynerba, and traded for about $9 a share. Now they trade for over $110 and GWPH is a $2 billion plus company. If Zynerba shows itself to be on a similar flight path to GWPH, expect to see some serious M&A buyers lining up to make a bid for Zynerba
Andy Biotech @AndyBiotech 5h5 hours ago @adamfeursein
$EXEL $BMY No question that nivo will be used before cabo, safety profile is the key (esp Gr3/4 SAEs)
By Solon Harmony B. Dolor in Market Movers
,News Published: October 5, 2015
Hedge funds buying Amicus Therapeutics ( FOLD )
100% with you . They are not going to split to $100 and then give not top of the line news.
another Wall Street fraud.